Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8300378 | Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms | 2018 | 35 Pages |
Abstract
In general, our work illustrates that it is the MAX to MYCN ratio that can account for tumour progression and clinical outcome in neuroblastoma and proposes that such a ratio should be considered as an important criterion to the design and development of anti-MYCN therapies.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Francesca Ferrucci, Roberto Ciaccio, Sara Monticelli, Paolo Pigini, Simone di Giacomo, Stefania Purgato, Daniela Erriquez, Roberto Bernardoni, Murray Norris, Michelle Haber, Giorgio Milazzo, Giovanni Perini,